MRVI - Maravai LifeSciences Holdings Inc Stock Price, Fair Value and News

$3.50+0.06 (+1.74%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MRVI Price Action

Last 7 days

-3.8%

Last 30 days

19.1%

Last 90 days

48.3%

Trailing 12 Months

-35.2%

MRVI RSI Chart

MRVI Valuation

Market Cap

506.4M

Price/Earnings (Trailing)

-4.19

Price/Sales (Trailing)

2.63

EV/EBITDA

-3.4

Price/Free Cashflow

-7.63

MRVI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MRVI Fundamentals

MRVI Revenue

Revenue (TTM)

192.4M

Rev. Growth (Yr)

-39.69%

Rev. Growth (Qtr)

-12.17%

MRVI Earnings

Earnings (TTM)

-121.0M

Earnings Growth (Yr)

73.67%

Earnings Growth (Qtr)

35.45%

MRVI Profitability

Operating Margin

21.07%

EBT Margin

-113.31%

Return on Equity

-28.02%

Return on Assets

-14.25%

Free Cashflow Yield

-13.1%

MRVI Investor Care

Shares Dilution (1Y)

2.21%

Diluted EPS (TTM)

-0.85

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	241.9M	219.8M	192.4M	0
2024	274.1M	274.6M	276.8M	259.2M
2023	717.7M	543.9M	419.5M	288.9M
2022	895.3M	920.3M	906.7M	883.0M
2021	381.3M	552.2M	669.1M	799.2M
2020	178.4M	213.6M	248.9M	284.1M
2019	0	0	0	143.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Maravai LifeSciences Holdings Inc

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

WEBSITE	maravai.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	660

Maravai LifeSciences Holdings Inc Frequently Asked Questions

What is the ticker symbol for Maravai LifeSciences Holdings Inc? What does MRVI stand for in stocks?

MRVI is the stock ticker symbol of Maravai LifeSciences Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Maravai LifeSciences Holdings Inc (MRVI)?

As of Wed Dec 03 2025, market cap of Maravai LifeSciences Holdings Inc is 506.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRVI stock?

You can check MRVI's fair value in chart for subscribers.

Is Maravai LifeSciences Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether MRVI is over valued or under valued. Whether Maravai LifeSciences Holdings Inc is cheap or expensive depends on the assumptions which impact Maravai LifeSciences Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRVI.

What is Maravai LifeSciences Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, MRVI's PE ratio (Price to Earnings) is -4.19 and Price to Sales (PS) ratio is 2.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRVI PE ratio will change depending on the future growth rate expectations of investors.